Y-mAbs Therapeutics Completes Merger with Perseus BidCo US

Y-mAbs Therapeutics, Inc. has completed its merger with Perseus BidCo US, Inc., as per the Agreement and Plan of Merger dated August 4, 2025. The merger was effected through a cash tender offer at $8.60 per share, which expired on September 15, 2025. Approximately 39.8 million shares, representing 87.22% of the outstanding shares, were tendered. The merger resulted in Y-mAbs becoming a wholly owned subsidiary of Perseus BidCo US. As a result, Y-mAbs requested the delisting of its shares from Nasdaq and the deregistration of its shares under the Securities Exchange Act of 1934. The aggregate consideration paid in the merger was approximately $413 million. Following the merger, several directors and officers resigned, and new directors and officers were appointed.